Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 9/20 | 0.54 |
| ▸ | SELL | P14151 | 3/20 | 0.52 |
| ▸ | SELE | P16581 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658273 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658269 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658274 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL21537086 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777275 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658272 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777277 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL23957944 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658268 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL13928698 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220233668-A1 | GLYCOPEPTIDE VACCINE | VICTORIA LINK LIMITED (NZ) | 2022-07-28 | — | — | US | disclosed |
| CN-114555629-A | Glycopeptide vaccines | 维多利亚联结有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3966229-A1 | GLYCOPEPTIDE VACCINE | Victoria Link Ltd (NZ) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231274-A1 | GLYCOPEPTIDE VACCINE | VICTORIA LINK LTD (NZ) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233668-A1 | GLYCOPEPTIDE VACCINE | FUT6, NGLY1, ST6GAL1 | APP 436/4885SELP 232/4885SELL 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.